These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18754290)

  • 1. Ultrasound assessment of endometrial thickness: correlation with ovarian stimulation and pregnancy rates in IVF cycles.
    Giannaris D; Zourla A; Chrelias C; Loghis C; Kassanos D
    Clin Exp Obstet Gynecol; 2008; 35(3):190-3. PubMed ID: 18754290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between endometrial thickness and pregnancy rates in GnRH antagonist down-regulated ICSI cycles.
    Kinay T; Tasci Y; Dilbaz S; Cinar O; Demir B; Haberal A
    Gynecol Endocrinol; 2010 Nov; 26(11):833-7. PubMed ID: 20504095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endometrial thickness dynamics and morphologic characteristics during pituitary downregulation with antagonists in assisted reproductive technology cycles.
    Detti L; Yelian FD; Kruger ML; Diamond MP; Puscheck EE
    J Ultrasound Med; 2008 Nov; 27(11):1591-6. PubMed ID: 18946098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction-intrauterine insemination to in vitro fertilization conversions, independent of age and estradiol level on the day of human chorionic gonadotropin administration.
    Quaas AM; Missmer SA; Ginsburg ES
    Fertil Steril; 2010 Feb; 93(2):605-8. PubMed ID: 19324340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of endometrial thickness on IVF/ICSI outcome.
    Kovacs P; Matyas S; Boda K; Kaali SG
    Hum Reprod; 2003 Nov; 18(11):2337-41. PubMed ID: 14585884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes.
    Papanikolaou EG; Bourgain C; Kolibianakis E; Tournaye H; Devroey P
    Hum Reprod; 2005 Jun; 20(6):1541-7. PubMed ID: 15705618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of estradiol/follicle and estradiol/oocyte ratios on the outcome of controlled ovarian stimulation for in vitro fertilization.
    Orvieto R; Zohav E; Scharf S; Rabinson J; Meltcer S; Anteby EY; Homburg R
    Gynecol Endocrinol; 2007 Feb; 23(2):72-5. PubMed ID: 17454155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histological evaluation of endometrium on the day of oocyte retrieval after gonadotrophin-releasing hormone agonist-follicle stimulating hormone ovulation induction for in-vitro fertilization.
    Lass A; Peat D; Avery S; Brinsden P
    Hum Reprod; 1998 Nov; 13(11):3203-5. PubMed ID: 9853881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endometrial ultrasonography as a predictor of pregnancy in an in-vitro fertilization programme after ovarian stimulation and gonadotrophin-releasing hormone and gonadotrophins.
    Oliveira JB; Baruffi RL; Mauri AL; Petersen CG; Borges MC; Franco JG
    Hum Reprod; 1997 Nov; 12(11):2515-8. PubMed ID: 9436697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of endometrial receptivity.
    Orvieto R; Meltzer S; Rabinson J; Zohav E; Anteby EY; Nahum R
    Fertil Steril; 2008 Oct; 90(4):1294-6. PubMed ID: 18178197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does the estradiol level on the day of human chorionic gonadotropin administration predict the clinical outcome of controlled ovarian hyperstimulation?
    Erzincan SG; Esmer AC; Baysal B
    Clin Exp Obstet Gynecol; 2014; 41(6):709-12. PubMed ID: 25551969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased endometrial thickness is associated with improved treatment outcome for selected patients undergoing in vitro fertilization-embryo transfer.
    Zhang X; Chen CH; Confino E; Barnes R; Milad M; Kazer RR
    Fertil Steril; 2005 Feb; 83(2):336-40. PubMed ID: 15705371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
    Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endometrial volume and thickness measurements predict pituitary suppression and non-suppression during IVF.
    Child TJ; Sylvestre C; Tan SL
    Hum Reprod; 2002 Dec; 17(12):3110-3. PubMed ID: 12456609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of endometrial and subendometrial vasculature on the day of embryo transfer and prediction of pregnancy during fresh in vitro fertilization cycles.
    Kim A; Jung H; Choi WJ; Hong SN; Kim HY
    Taiwan J Obstet Gynecol; 2014 Sep; 53(3):360-5. PubMed ID: 25286791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
    Humaidan P; Van Vaerenbergh I; Bourgain C; Alsbjerg B; Blockeel C; Schuit F; Van Lommel L; Devroey P; Fatemi H
    Hum Reprod; 2012 Nov; 27(11):3259-72. PubMed ID: 22930004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dynamics of endometrial growth and the triple layer appearance in three different controlled ovarian hyperstimulation protocols and their influence on IVF outcomes.
    Kuć P; Kuczyńska A; Topczewska M; Tadejko P; Kuczyński W
    Gynecol Endocrinol; 2011 Nov; 27(11):867-73. PubMed ID: 21231852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up.
    Kolibianakis E; Bourgain C; Albano C; Osmanagaoglu K; Smitz J; Van Steirteghem A; Devroey P
    Fertil Steril; 2002 Nov; 78(5):1025-9. PubMed ID: 12413988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.